BPC-157: what it is and what the evidence says
A peptide associated with the signaling processes of tissue repair; it is studied for its relationship with angiogenesis and the recovery of soft tissue and the digestive tract.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Tissue repair happens in phases, not all at once: an initial inflammation that is actually useful, the building of new tissue, and then its remodeling, which can take months. Compounds studied in this area relate to one of those phases. None of them replaces rest or rehabilitation, and that is precisely the most common mistake people make when reading about them.
What it is studied for
Recovery, tissue repair, gut health.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
In people there are three small studies with no control group: a 2021 series of injections into the knee joint, a 2024 pilot in interstitial cystitis, and a 2025 intravenous safety pilot in two healthy adults. In 2026 the first randomized, double-blind, placebo-controlled trial began recruiting, in muscle injury.
The limitation that matters most
Almost all the positive results come from rodent studies, most of them from a single group in Zagreb. Published randomized trials, human pharmacokinetics, and long-term safety data are still missing; the phase II program in inflammatory bowel disease did not publish its full results.
Regulatory status
Not approved by any regulatory agency. In the United States, the FDA removed it from Category 2 in April 2026 and its advisory committee voted in July 2026 in favor of allowing pharmacies to compound it, a recommendation that still needs a rule to take effect. Prohibited at all times in sport by WADA (section S0).
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
It is not approved by any agency and its interactions are not well characterized. Because it supports new vessel formation, a history of cancer is reviewed with your doctor, and product purity and source matter.
With active injuries, diagnosed digestive conditions, or ongoing medication, professional assessment is essential.
What this page cannot give you
A reference page can take you this far. You know what BPC-157 is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Reviewreview HSS J · 2025 · PMID 40756949 →
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healingreview Curr Rev Musculoskelet Med · 2025 · PMID 40789979 →
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performancereview Sports Med · 2026 · PMID 41966639 →
- Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?review Arthroscopy · 2025 · PMID 39265666 →
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Painhuman Altern Ther Health Med · 2021 · PMID 34324435 →
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Studyhuman Altern Ther Health Med · 2024 · PMID 39325560 →
- Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular responsereview Inflammopharmacology · 2006 · PMID 17186181 →
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationpreclinical J Appl Physiol (1985) · 2011 · PMID 21030672 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for BPC-157 or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is BPC-157?
A peptide associated with the signaling processes of tissue repair; it is studied for its relationship with angiogenesis and the recovery of soft tissue and the digestive tract. It is studied within the area of regenerative.
Is there human evidence for BPC-157?
In people there are three small studies with no control group: a 2021 series of injections into the knee joint, a 2024 pilot in interstitial cystitis, and a 2025 intravenous safety pilot in two healthy adults. In 2026 the first randomized, double-blind, placebo-controlled trial began recruiting, in muscle injury.
Is it approved by any health agency?
Not approved by any regulatory agency. In the United States, the FDA removed it from Category 2 in April 2026 and its advisory committee voted in July 2026 in favor of allowing pharmacies to compound it, a recommendation that still needs a rule to take effect. Prohibited at all times in sport by WADA (section S0).
What is the dose of BPC-157?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what BPC-157 is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.